Medscape1 个月
The Diagnostic Role and Clinical Relevance of Determination of BRAF Status in Brain Tumors
No writing assistance was utilized in the production of this manuscript. BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK ...
Yahoo Finance26 天
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF ...
NEW YORK, December 20, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ® (encorafenib) in combination with ...
Morningstar25 天
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF ...
“As the first and only combination regimen featuring a BRAF-targeted therapy for this patient population, usable even in first-line treatment, the encorafenib regimen has demonstrated high ...
Stockhouse26 天
U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF ...
(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 ...